Table 3_Altered expression of ADAR1, N4BP1, and PSME1 in PBMCs correlated with therapeutic

A prospective clinical study from an unspecified region followed HBeAg-negative chronic hepatitis B patients treated with Peg-IFN-α for 48 weeks. Hao Pang authored this dataset, which contains mRNA expression levels of ADAR1, N4BP1, and PSME1 in peripheral blood mononuclear cells, correlated with virological and serological response outcomes. The dataset was last updated on 2026-04 13.

Use Cases

• Predicting virological response to Peg-IFN-α therapy based on ADAR1, N4BP1, and PSME1 mRNA levels.
• Identifying patients likely to achieve HBsAg clearance based on biomarker expression dynamics.
• Building classification models for therapeutic outcome using multivariate analysis results from the study.
• Evaluating the diagnostic performance of novel biomarkers via ROC curve and AUC analysis.

Strengths

• Contains data from a prospective clinical study with a 48-week follow-up period.
• Includes specific AUC values for biomarker predictive performance (e.g., ADAR1 AUC of 0.9230 for VR at week 24).
• Response rates are explicitly quantified (VR rate 47.25%, SR rate 35.16%).
• Released under a permissive CC-BY-4.0 license.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (16.4 KB), indicating limited scope.

Provenance

Source

figshare, author Hao Pang.

Collection Method

Real-time quantitative PCR detection of mRNA levels in PBMCs from patients in a clinical trial.

Time Range

Study follow-up period of 48 weeks.

Freshness

Last updated 2026-04-13 04:36:08; freshness should be verified.

Geography

null